In last trading session, Sonnet BioTherapeutics Holdings Inc (NASDAQ:SONN) saw 0.27 million shares changing hands with its beta currently measuring 0.50. Company’s recent per share price level of $1.55 trading at -$0.23 or -12.92% at ring of the bell on the day assigns it a market valuation of $4.66M. That closing price of SONN’s stock is at a discount of -1107.74% from its 52-week high price of $18.72 and is indicating a premium of 9.03% from its 52-week low price of $1.41. Taking a look at company’s average trading volume for last 10-days demonstrates a volume of 0.36 million shares which gives us an average trading volume of 1.38 million if we extend that period to 3-months.
For Sonnet BioTherapeutics Holdings Inc (SONN), analysts’ consensus is at an average recommendation of Buy while assigning it a mean rating of 1.00. Splitting up the data highlights that, out of 2 analysts covering the stock, 0 rated the stock as a Sell while 0 recommended an Overweight rating for the stock. 0 suggested the stock as a Hold whereas 2 see the stock as a Buy. 0 analyst(s) advised it as an Underweight.
Sonnet BioTherapeutics Holdings Inc (NASDAQ:SONN) trade information
Upright in the red during last session for losing -12.92%, in the last five days SONN remained trading in the green while hitting it’s week-highest on Monday, 01/06/25 when the stock touched $1.55 price level, adding 38.49% to its value on the day. Sonnet BioTherapeutics Holdings Inc’s shares saw a change of 6.16% in year-to-date performance and have moved 6.16% in past 5-day. Sonnet BioTherapeutics Holdings Inc (NASDAQ:SONN) showed a performance of -26.19% in past 30-days. Number of shares sold short was 40115.0 shares which calculate 0.03 days to cover the short interests.
Weighing up company’s earnings over the past 5-year and in the next 5-year periods, we find the company posting an annual earnings growth rate of 85.27% during past 5 years.
Sonnet BioTherapeutics Holdings Inc (NASDAQ:SONN)’s Major holders
Insiders are in possession of 1.38% of company’s total shares while institution are holding 0.20 percent of that, with stock having share float percentage of 0.20%. Investors also watch the number of corporate investors in a company very closely, which is 0.20% institutions for Sonnet BioTherapeutics Holdings Inc that are currently holding shares of the company.
